All product information provided is intended for European Union audiences only. These products may not be available in all Member States of the EU or in countries outside the EU; they may be available under a different trademark, in different strengths, or for different indications. Countries outside the EU may have different regulatory and labeling requirements that would call for different information to be available.
*RISPERDAL CONSTA®, TREVICTA® and XEPLION®, Janssen products, utilize Alkermes’ proprietary extended-release microsphere technology, proprietary technology and proprietary nanoparticle injectable extended-release technology, respectively.
FAMPYRA® is a registered trademark of Acorda Therapeutics, Inc. RISPERDAL CONSTA®, TREVICTA® and XEPLION® are registered trademarks of Johnson & Johnson or its affiliated companies.